Sunshine Biopharma Inc. - SBFM STOCK NEWS

Sunshine Biopharma (OTC PINK: SBFM) announced the launch of its new eCommerce website, Nutrition.SunshineBiopharma.com, featuring over 20 nutritional products, including amino acids and vitamins. The site supports customers in browsing and ordering supplements conveniently. Essential 9™, one of the featured products, contains all nine essential amino acids crucial for protein synthesis and immune support. With eCommerce sales projected to grow from $374 billion in 2020 to $476 billion by 2024, Sunshine aims to enhance its market presence while maintaining strict manufacturing standards.

Sunshine Biopharma (SBFM) has launched its new eCommerce website, Nutrition.SunshineBiopharma.com, featuring over 20 nutritional products, including Essential 9™, designed to support optimal health. The website aims to enhance the shopping experience for consumers seeking high-quality nutritional supplements, available 24/7. With eCommerce sales projected to rise from $374 billion in 2020 to $476 billion by 2024, the launch positions SBFM to capitalize on the growing market.

Sunshine Biopharma (OTC PINK:SBFM) announced the start of a critical transgenic mice study for its COVID-19 treatment, aimed at inhibiting virus replication via protease inhibitors. The study, conducted at the University of Georgia, uses genetically modified mice susceptible to SARS-CoV-2. Success in these studies may lead to FDA submissions for human trials. Sunshine Biopharma's COVID-19 treatment has seen progress since its provisional patent filing in May 2020, with a lead compound identified as SBFM-PL4.

Sunshine Biopharma (OTC PINK:SBFM) announced an exclusive license agreement with the University of Georgia for two patented Anti-Coronavirus compounds. This partnership aims to advance the compounds' development alongside SBFM-PL4, Sunshine's lead Anti-Coronavirus compound. The efficacy testing will involve genetically modified mice susceptible to SARS-CoV-2, with trials expected to commence this month. Furthermore, Sunshine is actively developing Adva-27a, an anticancer drug targeting multidrug-resistant cancer cells and planning clinical trials for pancreatic cancer.

Sunshine Biopharma (OTC PINK:SBFM) has successfully paid off over $100,000 in convertible notes, aiming to reduce dilution and enhance shareholder value. The CFO, Camille Sebaaly, expressed commitment to operational growth and prioritizing shareholders' interests. The company continues its development on SBFM-PL4, a COVID-19 treatment in collaboration with the University of Georgia, and Adva-27a, an anticancer compound effective against multidrug-resistant cancers. Clinical trials for Adva-27a are planned at McGill University.

Sunshine Biopharma Inc. (OTC PINK:SBFM) announced receiving the third tranche of $800,000 from a $2,000,000 financing agreement with RB Capital Partners Inc. This funding supports the priority development of their Coronavirus treatment and clinical advancement of Adva-27a, an anticancer drug targeting pancreatic cancer. The company aims to combat SARS-CoV-2 through new molecules that inhibit viral replication. Ongoing testing and collaboration with the University of Georgia are key aspects of their development strategy.

Sunshine Biopharma (OTC PINK:SBFM) is advancing its Anti-Coronavirus drug development amidst the ongoing pandemic. Recognizing the necessity for effective treatments alongside vaccines, the company emphasizes the importance of an oral treatment option. Sunshine Biopharma has filed a provisional patent for novel compounds inhibiting Coronavirus proteases, with lead candidate SBFM-PL4 currently in in vitro testing. Additionally, the company is developing Adva-27a, an anticancer drug showing efficacy against multidrug-resistant cancers, with clinical trials planned at McGill University.

Sunshine Biopharma Inc. (OTC PINK:SBFM) has entered into a collaboration agreement with a Montreal-based company to advance its anticancer compound, Adva-27a. This partnership aims to develop chemical synthesis procedures and test the compound on various cancer cells. Following successful cell culture tests, mice studies will be conducted to prepare for clinical trials targeting Stage IV pancreatic cancer at McGill University’s Jewish General Hospital in Montreal. Adva-27a has shown effectiveness against multidrug-resistant cancer cells, including those from pancreatic cancer.

Sunshine Biopharma Inc. (OTC PINK:SBFM) announced it has secured a second tranche of funding totaling $550,000 from RB Capital Partners under a $2 million financing agreement. The funds will support the development of its Coronavirus treatment and the clinical development of Adva-27a, its lead anticancer drug. SBFM-PL4, a lead compound targeting Coronavirus proteases, is currently progressing through testing phases in collaboration with the University of Georgia. The company is also conducting trials for Adva-27a aimed at treating multidrug-resistant cancers, including pancreatic cancer.